DaVita Inc. (DVA) $232.80
DaVita trades at a massive premium, testing the upper limits of its range with an RSI that screams caution.
52-wk High $239.64
📌 Investment Snapshot
- Price $232.80 sits at 95% of the 52-week high.
- Q1 2026 Revenue $3.42B with EPS of $2.87.
- Momentum remains aggressive with a 55% 3-month return.
- Consensus target of $197.14 implies 15% downside risk.
DVA trades in extreme overbought territory with an RSI of 83.3. The current price sits well above analyst consensus targets, signaling a disconnect between momentum and fundamental valuation.
| 📍 Entry Zone | $200.00 or below | 🛑 Stop-Loss | $190.00 |
| 📋 Adjust If | Price reclaims $240 with volume expansion. | ||
The Investment Case — Why Now?
DaVita enjoyed a parabolic run, fueled by aggressive institutional accumulation and strong quarterly prints. The stock now sits well above its 50-day SMA, which indicates a stretched valuation that leaves little room for error.
The primary risk involves the mean reversion of such a rapid ascent. With the stock trading nearly 15% above the consensus price target, the risk-to-reward profile currently favors the bears.
🤔 Given the 55% three-month rally, are you chasing momentum or waiting for a technical reset?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
📈 Price Action & Technicals
Golden Cross
Outside VA
Buy-side Sweep at $191.57 on 2026-06-02
The stock trades well above the 50-day and 200-day moving averages, confirming a powerful uptrend. However, the RSI at 83.3 signals an extreme overbought condition that historically precedes a cooling-off period.
Volume runs at 88% of the 20-day average, which suggests the current push lacks the conviction of earlier legs. A failure to hold the $224 support zone could trigger a rapid slide toward the $215 gap.
The anchored VWAP from January at $163.21 sits far below current levels, highlighting how disconnected the price has become from its trend-line foundation.
Liquidity sweeps at $202 and $191 suggest institutional interest, but the current price action feels like a blow-off top.
Wait for the price to retest the $200–$204 FVG zone before considering a long entry.
🤔 Does the current volume profile support a breakout above $240, or is this a classic exhaustion rally?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| DVA | DaVita Inc. | 22.4x |
| SPY | S&P 500 | 21.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $3.42B | $2.87 | +1.1% |
| Q4 2025 | $3.62B | $3.22 | +5.8% |
| Q3 2025 | $3.42B | $2.04 | +0.0% |
| Q2 2025 | $3.38B | $2.58 | +1.2% |
Free cash flow remains stable at $0.2B, with management utilizing $0.4B for buybacks.
Earnings growth has remained steady, but the current stock price appreciation far outpaces the underlying EPS expansion.
🚀 Growth Drivers — What Moves the Stock
- Dialysis Volume Stability 🟡 Priced In — Core business operations remain predictable despite macro headwinds.
- Operational Efficiency 🟢 Upside Surprise — Margin expansion initiatives continue to drive bottom-line results.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Berkshire Hathaway, Inc | 30,100 |
| Blackrock Inc. | 2,766 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| RODRIGUEZ JAVIER J | CEO | 2026-06-16 | Sale | 69407 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 13.8% | 5.4 |
⚠ Key Risk Factors
~$0.5B impact
~$1.2B impact
🤔 Does the high short interest combined with an overbought RSI signal a potential short squeeze or a pending correction?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $235.00 | $197.14 | $145.00 | 7 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| UBS | Buy | $N/A | 2026-07-10 | Main |
Analysts remain cautious, with the mean target significantly below the current market price.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Strong institutional backing from Berkshire Hathaway.
- Consistent margin expansion.
📊 Base Case
The stock consolidates near current levels as fundamentals catch up to price.
🐻 Bear Case
- Extreme RSI indicates exhaustion.
- Price trades well above analyst consensus.
🎯 Investor Action Plan — By Profile
Avoid new longs until the RSI cools below 60.
Wait for a retest of the $200 support level.
Maintain existing positions but avoid adding at these levels.
❓ Investor FAQ — People Also Ask
Q: Why is the verdict WAIT despite the strong momentum?
The RSI of 83.3 indicates extreme overbought conditions, and the price trades 15% above the consensus target.
Q: What is the key support level to watch?
The $200–$204 zone represents a key unfilled FVG and a logical area for a technical retest.
Q: Does the short interest pose a risk?
With 13.8% of the float shorted, any sharp reversal could trigger volatility, but the primary trend remains overextended.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 For real-time updates and advanced charting tools,
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Always conduct your own due diligence.
All active positions and their real-time performance are tracked on our Investment Log.
#DVA #DaVita #Healthcare #StockMarket #Investing #TechnicalAnalysis #Trading #WallStreet